Pharmacokinetics of gefitinib predicts the antitumor activity for advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Nakamura, Y.
Sano, K.
Fukuda, M.
Takatani, H.
Nagashima, S.
Kinoshita, A.
Fukuda, M.
Soda, H.
Oka, M.
Kohno, S.
机构：
[1] Goto Cent Hosp, Goto, Japan
[2] Meiji Pharmaceut Univ, Tokyo, Japan
[3] Nagasaki Thorac Oncol Grp, Nagasaki, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：81S / 81S
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics of gefitinib predicts the antitumor activity for advanced non-small cell lung cancer (NSCLC)
    Iida, Tetsuya
    Nakamura, Yoichi
    Fukuda, Masaski
    Takatani, Hiroshi
    Nagashima, Seiji
    Kinoshita, Akitoshi
    Fukuda, Minoru
    Soda, Hiroshi
    Oka, Mikio
    Kohno, Shigeru
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S462 - S462
  • [2] Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer
    Nakamura, Yoichi
    Sano, Kazumi
    Soda, Hiroshi
    Takatani, Hiroshi
    Fukuda, Minoru
    Nagashima, Seiji
    Hayashi, Tomayoshi
    Oka, Mikio
    Tsukamoto, Kazuhiro
    Kohno, Shigeru
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (09) : 1404 - 1409
  • [3] Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC)
    Bearz, Alessandra
    Fratino, Lucia
    Spazzapan, Simon
    Berretta, Massimiliano
    Giacalone, Annalisa
    Simonelli, Cecilia
    Tirelli, Umberto
    LUNG CANCER, 2007, 55 (01) : 125 - 127
  • [4] Gefitinib for advanced non-small cell lung cancer
    Sim, Esther H. A.
    Yang, Ian A.
    Wood-Baker, Richard
    Bowman, Rayleen V.
    Fong, Kwun M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (01):
  • [5] Gefitinib in advanced non-small cell lung cancer
    Sharma, R
    Boyer, M
    Clarke, S
    Millward, M
    INTERNAL MEDICINE JOURNAL, 2005, 35 (02) : 77 - 82
  • [6] The BC Cancer Agency experience with gefitinib in advanced non-small cell lung cancer (NSCLC)
    Ho, C
    Murray, N
    Melosky, B
    Laskin, J
    Anderson, H
    Karim, RR
    Hamata, L
    Bebb, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 220S - 220S
  • [7] Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Papachristos, A.
    Masinde, S.
    Davis, J. D.
    Gullo, G.
    Rietschel, P.
    Paccaly, A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S308 - S309
  • [8] Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients
    Chang, Gee-Chen
    Tsai, Chun-Ming
    Chen, Kun-Chieh
    Yu, Chong-Jen
    Shih, Jin-Yuan
    Yang, Tsung-Ying
    Lin, Ching-Pei
    Hsu, Jeng-Yuan
    Chiu, Chao-Hua
    Perng, Reury-Perng
    Yang, Pan-Chyr
    Yang, Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (06) : 520 - 525
  • [9] Apatinib to enhance antitumor activity of gefitinib in non-small cell lung cancer.
    Li, Fang
    Zhu, Tengjiao
    Zhu, Xiang
    Wang, Jiadong
    Liang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Factors predicting the efficacy of gefitinib in patients with advanced non-small cell lung cancer (NSCLC).
    Kishi, K
    Homma, S
    Miyamoto, A
    Sakamoto, S
    Motoi, N
    Yoshimura, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 644S - 644S
12345